Takeda gets European panel nod for Alunbrig to treat lung cancer
The European Medicines Agency's Committee for Medicinal Products for Human Use recommended granting Japan-based Takeda's Alunbrig, or brigatinib, a marketing authorisation.
New Delhi; Takeda Pharmaceutical Co's lung cancer drug received the recommendation of a European Union panel on Friday, more than a year after it won regulatory approval to be sold in the United States.
The European Medicines Agency's Committee for Medicinal Products for Human Use recommended granting Japan-based Takeda's Alunbrig, or brigatinib, a marketing authorisation.
The panel's recommendations are generally followed by European regulators.
Alunbrig was approved last year by the U.S. Food and Drug Administration as a second-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer, who have progressed on or are intolerant to Pfizer drug crizotinib, the standard initial treatment for the disease.
(Reporting by Sangameswaran S in Bengaluru; Editing by Sai Sachin Ravikumar)
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd